Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705319 | 0.76 | ROCK2 (0.44) | ROCK2KCNH2NOS2LMNAAPEX1 | |
| SCHEMBL22289328 | 0.72 | HCAR2 (0.40) | — | |
| SCHEMBL28209770 | 0.72 | NOS2 (0.35) | ROCK2KCNH2NOS2LMNAAPEX1 | |
| SCHEMBL2353201 | 0.69 | — | — | |
| SCHEMBL7034982 | 0.69 | KMT2A (0.47) | — | |
| SCHEMBL3831425 | 0.68 | CHRM5 (0.41) | ROCK2PIM1LMNAROCK1 | |
| SCHEMBL2583498 | 0.68 | ROCK2 (0.44) | ROCK2KCNH2NOS2LMNAAPEX1 | |
| SCHEMBL16834685 | 0.67 | ROCK2 (0.50) | ROCK2ROCK1 | |
| SCHEMBL1427632 | 0.67 | OXTR (0.49) | LMNA | |
| SCHEMBL1532886 | 0.67 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4210694-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230002326-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-01-05 | — | — | US | disclosed |
| EP-3976577-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2022-03-17 | — | — | US | disclosed |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020243373-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10806719-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-10806720-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200299243-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-09-24 | — | — | US | disclosed |
| US-10654809-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200039924-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-02-06 | — | — | US | disclosed |
| US-10314797-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190015387-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180273487-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-09-27 | — | — | US | disclosed |
| US-20170368003-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314797-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-20200299243-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-11230523-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ROCK2 4395/4885KCNH2 3778/4885PIM1 2907/4885 |
| US-20210161864-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE | AR, BRCA1, FSHR | ROCK2 4459/4885KCNH2 4012/4885PIM1 4762/4885 |
| US-20220081401-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4395/4885KCNH2 3778/4885PIM1 2907/4885 |
| US-20230002326-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4295/4885KCNH2 3627/4885PIM1 3845/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | ROCK2 4459/4885KCNH2 4012/4885PIM1 4762/4885 |
| US-10654809-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-10806719-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ROCK2 4230/4885KCNH2 3633/4885PIM1 3856/4885 |
| US-20180273487-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-20170368003-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-10806720-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | ROCK2 4482/4885KCNH2 4141/4885PIM1 4753/4885 |
| US-11230531-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
| US-20200039924-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4395/4885KCNH2 3778/4885PIM1 2907/4885 |
| US-20190015387-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, AHR | ROCK2 4343/4885KCNH2 3470/4885PIM1 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.